Production (Stage)
Mineralys Therapeutics, Inc.
MLYS
$16.12
$0.503.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.75% | 17.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.14% | -13.87% | |||
| Operating Income | 14.14% | 13.87% | |||
| Income Before Tax | 13.76% | 13.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.76% | 13.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.76% | 13.13% | |||
| EBIT | 14.14% | 13.87% | |||
| EBITDA | 14.14% | 13.88% | |||
| EPS Basic | 18.95% | 13.38% | |||
| Normalized Basic EPS | 18.96% | 13.38% | |||
| EPS Diluted | 18.95% | 13.38% | |||
| Normalized Diluted EPS | 18.96% | 13.38% | |||
| Average Basic Shares Outstanding | 6.42% | 0.29% | |||
| Average Diluted Shares Outstanding | 6.42% | 0.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||